Table 1. Demographic and clinical characteristics of all patients separated by genotype.
| Characteristic | Total n = 826 | Genotype 1 n = 204 | Genotype 2 n = 25 | Genotype 3 n = 253 | Genotype 6 n = 344 |
|---|---|---|---|---|---|
| Subtype | |||||
| a | 33 (16%) | 25 (100%) | 124 (49%) | 321 (93%) | |
| b | 171 (84%) | -- | 129 (51%) | -- | |
| n | -- | -- | -- | 19 (6%) | |
| v | -- | -- | -- | 3 (1%) | |
| u | -- | -- | -- | 1 (0%) | |
| Gender | |||||
| Male | 631 (76%) | 154 (75%) | 15 (60%) | 198 (78%) | 264 (77%) |
| Female | 194 (24%) | 50 (25%) | 10 (40%) | 55 (22%) | 79 (23%) |
| Age | |||||
| <30 | 84 (10%) | 24 (12%) | 0 (0%) | 29 (11%) | 31 (9%) |
| 30–40 | 420 (51%) | 103 (51%) | 10 (40%) | 138 (54%) | 169 (49%) |
| 40–50 | 275 (33%) | 66 (33%) | 9 (36%) | 76 (30%) | 124 (36%) |
| >50 | 45 (5%) | 10 (5%) | 6 (24%) | 10 (4%) | 19 (6%) |
| Route of Transmission | |||||
| Sexual | 178 (22%) | 39 (19%) | 4 (16%) | 52 (21%) | 83 (24%) |
| Blood | 58 (7%) | 35 (17%) | 14 (56%) | 3 (1%) | 6 (2%) |
| IVDU | 566 (69%) | 118 (58%) | 5 (20%) | 191 (75%) | 252 (73%) |
| Unknown | 22 (3%) | 11 (5%) | 2 (8%) | 7 (3%) | 2 (1%) |
| Median CD4 count* (range) | 126 (31–241) | 103 (24–211) | 198 (121–338) | 150 (42–254) | 115.5 (30–237) |
| Median ALT | 38 (27–60) | 38.5 (27–67) | 30 (24–41) | 38 (26–61) | 37.5 (27–57) |
| Median AST | 35 (20–58) | 36 (20–63) | 21 (15–37) | 33 (20–50) | 34 (20–58) |
| Median Log10 HCV RNA | 6.1 (5.5–6.6) | 6.2 (5.6–6.7) | 6.1 (5.5–6.6) | 5.9 (5.4–6.4) | 6.3 (5.7–6.8) |
CD4 count expressed as cells/uL (n = 813); ALT = alanine aminotransferase (units/L) (n = 561); AST = aspartate aminotransferase (units/L) (n = 561); HCV RNA expressed as IU/mL (n = 415)
*Obtained at time of enrollment in study